1056267-89-0

Basic information

• Product Name: 6-BroMo-2H-1,4-benzoxazine-3(4H)-thione
• Synonyms: 6-BroMo-2H-1,4-benzoxazine-3(4H)-thione;6-bromo-2H-benzo[b][1,4]oxazine-3(4H)-thione
• CAS NO: 1056267-89-0
• Molecular Formula: C8H6BrNOS
• Molecular Weight: 244.10834
• Mol File: 1056267-89-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Solubility: DCM, DMSO, Methanol
• CAS DataBase Reference: 6-BroMo-2H-1,4-benzoxazine-3(4H)-thione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-2H-1,4-benzoxazine-3(4H)-thione(1056267-89-0)
• EPA Substance Registry System: 6-BroMo-2H-1,4-benzoxazine-3(4H)-thione(1056267-89-0)

Safety Data

• Hazardous Substances Data: 1056267-89-0(Hazardous Substances Data)

Usage

Uses

6-Bromo-2H-1,4-benzoxazine-3(4H)-thione is an intermediate in the synthesis of NS-2028 (N900200), potent soluble guanylyl cyclase (sGC) inhibitor (Ki = 8 nM). NS-2028 blocks sGC activity in murine cerebellum induced by S-nitroso-glutathione and NMDA.

Upstream product

• 24036-52-0 6-bromo-3,4-dihydro-2H-1,4-benzoxazin-3-one 

Relevant articles and documents

PD-1 inhibitor as well as preparation method and application thereof

The present invention relates to a compound represented by a formula I, racemates, stereoisomers, tautomers, isotope markers, nitrogen oxide, solvates, polymorphs, metabolites, esters, prodrugs or pharmaceutically acceptable salts thereof, a pharmaceutical composition containing the compounds, a preparation method and a medical use of the compounds, wherein the structure of the formula I is shownin the specification.

Metalloprotease inhibitors containing a heterocyclic moiety

The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.